We scan new podcasts and send you the top 5 insights daily.
Alex Rives says health-record models learn correlations, which can route existing drugs to the right patients better but won't uncover causal biology. Biohub instead focuses on fundamental measurement and models, arguing that without the right basis, patient-history AI cannot explain the truly deep underlying mechanisms of disease.
The bottleneck for AI in drug discovery is not the algorithm but the lack of high-quality, large-scale biological data. New platforms are needed to generate this necessary "substrate" for AI models to learn from, challenging the narrative that better models alone are the solution.
Alex Rives says continuous molecular monitoring would be immensely valuable and likely converge with cell models eventually. Measuring more molecular parameters continuously could directly link bottom-up personal health data with top-down biological understanding of disease, though Biohub itself stays at the enabling technology layer.
Standard AI models trained on public, observational biological data excel at descriptive tasks but underperform even linear models on causal predictions. To predict cellular responses to drug-like perturbations, models must be trained specifically on causal data generated from targeted experiments.
In a skeptical, regulated industry, simply predicting an outcome is insufficient. Causal AI is non-negotiable because it provides a 'glass box' explanation for its recommendations. It connects outputs to data points and biological reasoning, satisfying the critical 'why' questions from both sponsors and regulators.
AI models trained on descriptive data (e.g., RNA-seq) can classify cell states but fail to predict how to transition a diseased cell to a healthy one. True progress requires generating massive "causal" datasets that show the effects of specific genetic perturbations.
Many promising biomarkers are merely correlated with a disease, not a cause. Developing effective drugs requires targeting mechanisms with a direct causal effect on the outcome. This distinction is so critical that Valo Health has a "Chief Causal AI Officer" role to emphasize the focus.
Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.
Alex Rives treats disease as a regular biological program encoded in human life, opening the door to programmable medicine. Reading and rewriting those programs could directly let interventions target underlying mechanisms rather than just surface symptoms, which is central to Biohub's ambitious human cure-all-disease mission.
Achieving explainability in AI for drug development isn't about post-hoc analysis. It requires building models from the ground up using inherently interpretable data like RNA sequencing and mutational profiles. When the inputs are explainable, the model's outputs become explainable by design.
Recent AI advancements in biotech are less about new algorithms and more about reaching a critical threshold of complete, high-quality data from electronic health records. This allows AI to extract genuine insights rather than just compensating for historical data shortcomings.